The FDA on May 30, 2024, approved BREYANZI® for adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton Tyrosine Kinase Inhibitor (BTKi). BREYANZI® is a product of Juno Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
